ArticleJournal of cancer research and clinical oncology2017
Survival of de novo stage IV breast cancer patients over three decades.
Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.NPJ breast cancer · 2025Article
- Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors.Breast cancer research : BCR · 2025Article
- Breast Reconstruction in De Novo Metastatic Breast Cancer: A Systematic Review.Plastic and reconstructive surgery. Global open · 2025Article
- Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.Acta oncologica (Stockholm, Sweden) · 2024Observational
- Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study.JCI insight · 2024Article
- Patterns of distant metastasis and survival outcomes inFrontiers in endocrinology · 2024Article
- The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker.Breast cancer (Dove Medical Press) · 2024Article
- Survival in male breast cancer over the past 3 decades.Journal of the National Cancer Institute · 2023Article
- Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data.Journal of cancer research and clinical oncology · 2023Review
- Article
- Volatile Organic Compounds Analysis as a Potential Novel Screening Tool for Breast Cancer: A Systematic Review.Biomarker insights · 2022Review
- Prediction of Breast Cancer Survival by Machine Learning Methods: An Application of Multiple Imputation.Iranian journal of public health · 2021Article
- Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis.Oncology letters · 2020Article
- En-Bloc Resection of Metastases of the Proximal Femur and Reconstruction by Modular Arthroplasty is Not Only Justified in Patients with a Curative Treatment Option-An Observational Study of a Consecutive Series of 45 Patients.Journal of clinical medicine · 2020Article
- Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Ulcerated breast cancer with single brain metastasis: A combined surgical approach. Clinical presentation at one year follow up - A case report.International journal of surgery case reports · 2020Article
- Incorporation of biologic factors for the staging of de novo stage IV breast cancer.NPJ breast cancer · 2020Article
- Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry).Scientific reports · 2019Article
- Does adjuvant therapy reduce postmetastatic survival?Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
- Metastatic breast cancer incidence, site and survival in Australia, 2001-2016: a population-based health record linkage study protocol.BMJ open · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDe novo stage IV breast cancer patients (BC
methodsBC
resultsBetween 1978 and 2013, 88,759 patients were diagnosed with 92,807 cases of invasive and non-invasive BC. Of these patients, 4756 patients had distant metastases (MET) at diagnosis. The 5-year survival rate improved from 17.4 to 24.7%, while the pattern of metastases did not change. Improved staging diagnostics, a screening programme and primary systemic therapy changed the composition of prognostic strata. Patients with a similar composition as the 1978-1987 cohort exhibited a median survival difference of 13 months; however, neither univariate nor multivariate analysis showed a survival effect for the four periods as a surrogate indicator for changing treatments. HER2+ patients have with 27.6 months a slightly longer survival than all other BC
conclusionsSurvival of de novo BC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.